Shire obtained FDA approval to market Vyvanse, or lisdexamfetamine dimesylate, as maintenance therapy for children and teenagers with attention deficit hyperactivity disorder. This makes Vyvanse the only stimulant approved for use as a maintenance therapy in all ADHD patients older than 6, Shire says. The approval was based on data from a 32-week trial that showed lower treatment-failure rate among those who received Vyvanse.
Shire's Vyvanse wins FDA nod as maintenance for pediatric ADHD
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||